类风湿关节炎患者骨折风险与血清学状态:一项人群回顾性队列研究
该研究基于韩国国民健康保险数据库,纳入2010–2017年确诊的类风湿关节炎(RA)患者43,677例及年龄性别匹配对照131,031例。结果显示RA患者任何骨折风险高于对照(aHR 1.68,95%CI 1.62‒1.75),血清阳性RA骨折风险更高,且无论是否使用bDMARD或tsDMARD骨折风险均升高。
要点
- RA患者任何骨折风险显著高于匹配对照(aHR 1.68,95%CI 1.62‒1.75)。
- 血清阳性RA较血清阴性RA骨折风险更高,髋部骨折aHR 1.55(95%CI 1.19‒2.02)。
- 无论是否使用bDMARD或tsDMARD,RA患者骨折风险均高于对照。
核心结论
- RA患者骨折风险高于无RA者,血清阳性RA风险更高。
- 无论是否使用bDMARD或tsDMARD,RA患者骨折风险均持续升高。
研究设计与样本
- 基于韩国国民健康保险服务数据库的人群回顾性队列研究。
- 纳入2010–2017年确诊RA患者43,677例及年龄性别匹配对照131,031例。
主要发现
- RA患者任何骨折风险高于匹配对照(aHR 1.68,95%CI 1.62‒1.75)。
- 血清阳性RA较血清阴性RA任何骨折aHR 1.19(95%CI 1.11‒1.28)。
- 血清阳性RA椎体骨折aHR 1.40(95%CI 1.26‒1.55),髋部骨折aHR 1.55(95%CI 1.19‒2.02)。
- 对照相比,bDMARD暴露者骨折风险为2.28倍、未暴露者1.64倍;tsDMARD暴露者1.91倍、未暴露者1.68倍。
临床怎么用
- 对RA患者,尤其血清阳性者,应积极监测骨折风险并及时干预。
- 使用bDMARD或tsDMARD期间仍需关注骨折风险,不能视为已消除。
局限性
- 原文未明确列出局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Patients with rheumatoid arthritis have higher fracture risks than those without RA, particularly in seropositive cases. The risk of fractures remained elevated regardless of bDMARD or tsDMARD use, warranting further large-scale studies. Our findings highlight the need for active surveillance and timely intervention in RA patients, particularly those with SPRA and regardless of bDMARD or tsDMARD use. OBJECTIVES: Evidence of the association between the serological status and the risk of fracture among patients with rheumatoid arthritis (RA) considering exposure to disease-modifying antirheumatic drugs (DMARDs) is scarce. We investigated the risk of fracture among patients with RA according to the serological status considering exposures to biologic DMARDs (bDMARDs) or targeted synthetic DMARDs (tsDMARDs). METHODS: We conducted a population-based retrospective cohort study using the Korean National Health Insurance Service database including patients who were diagnosed with RA between 2010 and 2017 (n = 43,677) and controls matched according to age and sex (n = 131,031). RESULTS: Patients with RA had a higher risk of any fractures compared to matched controls (adjusted hazard ratio [aHR] 1.68, 95% confidence interval [CI] 1.62‒1.75). Patients with seropositive RA (SPRA) had an increased risk of fracture (aHR 1.19, 95% CI 1.11‒1.28 for any fractures; aHR 1.40, 95% CI 1.26‒1.55 for vertebral fractures; aHR 1.55, 95% CI 1.19‒2.02 for hip fractures) compared to those with seronegative RA. Compared to matched controls, RA patients showed higher fracture risk regardless of bDMARDs (exposed: 2.28-fold; unexposed: 1.64-fold) or tsDMARDs (exposed: 1.91-fold; unexposed: 1.68-fold). CONCLUSION: Patients with RA were at higher risk of fractures compared to those without RA, with even higher risk among those with SPRA. The risk of fractures remained elevated regardless of bDMARD or tsDMARD use, warranting further studies to explore the impact of bDMARDs and tsDMARDs on fracture risk in patients with RA.
引用
- Kim S, Han KD, Jung J, et al. Risk of fracture among patients with rheumatoid arthritis according to serological status: a population-based retrospective cohort study. Osteoporos Int. 2026. PMID: 42047755. doi:10.1007/s00198-026-08028-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。